Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 1:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neuroprotection Clear all
Terminated Phase 3 Interventional Results available

Albumin in Acute Ischemic Stroke Trial

NCT00235495
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Albumin, Saline
Biological · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 83 Years
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
69
States / cities
Phoenix, Arizona • Tucson, Arizona • Concord, California + 48 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 22, 2026, 1:34 AM EDT
Completed Not applicable Interventional Results available

Delayed Rewarming for Neuroprotection in Infants Following Cardiopulmonary Bypass Surgery

NCT03036072
View directory record Official record
Conditions
Post-Op Complication
Interventions
Strict normothermia, Delayed Rewarming
Other · Device
Lead sponsor
Alexa Craig
Other
Eligibility
Up to 6 Months
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Jul 12, 2020 · Synced Sep 22, 2026, 1:34 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate Safety and Efficacy of KM-819 in Healthy Adults and Participants with Parkinson's Disease

NCT05670782
View directory record Official record
Conditions
Parkinson Disease
Interventions
KM-819, Placebo
Drug
Lead sponsor
FAScinate Therapeutics Inc.
Industry
Eligibility
40 Years and older
Enrollment
314 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
3
States / cities
Glendale, California • San Diego, California • Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Sep 22, 2026, 1:34 AM EDT
Terminated Phase 1 Interventional

Oral Guanabenz for Multiple Sclerosis

NCT02423083
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis
Interventions
Guanabenz
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 55 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 22, 2026, 1:34 AM EDT
Recruiting Phase 1Phase 2 Interventional

Verapamil for Neuroprotection in Stroke

NCT03347786
View directory record Official record
Conditions
Ischemic Stroke
Interventions
10 mg Intra-arterial Verapamil, 20 mg Intra-arterial Verapamil
Drug
Lead sponsor
Global Neurosciences Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
3
States / cities
Atlantic City, New Jersey • Langhorne, Pennsylvania • Upland, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Sep 22, 2026, 1:34 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Inhaled Nitric Oxide and Neuroprotection in Premature Infants

NCT00515281
View directory record Official record
Conditions
Prematurity, Bronchopulmonary Dysplasia, Intraventricular Hemorrhage, Periventricular Leukomalacia
Interventions
inhaled nitric oxide, oxygen
Drug
Lead sponsor
University of Chicago
Other
Eligibility
2 Hours to 72 Hours
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Sep 22, 2026, 1:34 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phenytoin as a Neuroprotective Agent Against Corticosteroid-induced Functional Imaging Changes

NCT00591006
View directory record Official record
Conditions
Healthy
Interventions
Phenytoin (brand name Dilantin), Hydrocortisone, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2015 · Synced Sep 22, 2026, 1:34 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effect of Talampanel (an AMPA Receptor Blocker) on Brain Activity

NCT00057460
View directory record Official record
Conditions
Healthy
Interventions
Talampanel
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 22, 2026, 1:34 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

N-Acetylcysteine for Neuroprotection in Parkinson's Disease

NCT01470027
View directory record Official record
Conditions
Parkinson Disease
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
50 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Sep 22, 2026, 1:34 AM EDT
Completed Phase 2 Interventional

Duration of Hypothermia for Neuroprotection After Pediatric Cardiac Arrest

NCT00797680
View directory record Official record
Conditions
Cardiac Arrest, Brain Injury
Interventions
72 hours hypothermia, 24 hours hypothermia
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
1 Week to 17 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 17, 2016 · Synced Sep 22, 2026, 1:34 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Parkinson's Disease Inflammatory Biomarker Profiling

NCT03633513
View directory record Official record
Conditions
Parkinson Disease
Interventions
LBT-3627, Immunological profiling
Diagnostic Test
Lead sponsor
Longevity Biotech
Industry
Eligibility
18 Years to 89 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Sep 22, 2026, 1:34 AM EDT
Terminated Not applicable Interventional Results available

Transcranial Direct Current Stimulation as a Neuroprotection in Acute Stroke Before and After Thrombectomy

NCT04061577
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Transcranial Direct Current Stimulation (tDCS)
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Sep 22, 2026, 1:34 AM EDT
Completed Phase 2Phase 3 Interventional

Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence (FASTER)

NCT00109382
View directory record Official record
Conditions
Transient Ischemic Attack, Stroke
Interventions
Aspirin, Clopidogrel, Simvastatin
Drug
Lead sponsor
University of Calgary
Other
Eligibility
40 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2008 · Synced Sep 22, 2026, 1:34 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Brain Imaging and Developmental Follow up of Infants Treated With Erythropoietin

NCT01207778
View directory record Official record
Conditions
Prematurity
Interventions
Not listed
Lead sponsor
University of New Mexico
Other
Eligibility
36 Months to 72 Months
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2020
U.S. locations
3
States / cities
Albuquerque, New Mexico • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Sep 22, 2026, 1:34 AM EDT
Withdrawn Phase 1 Interventional

Superselective Citicoline and Verapamil for Ischemic Neuroprotection and Greater Effective Response

NCT02823106
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Verapamil and Citicoline, Placebo
Drug · Other
Lead sponsor
Justin Fraser
Other
Eligibility
18 Years to 101 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Sep 22, 2026, 1:34 AM EDT
Terminated Not applicable Interventional

Vision Preservation and Restoration Following a 6 Month Trial of GlaucoCetin

NCT04784234
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
GlaucoCetin, Placebo
Dietary Supplement · Other
Lead sponsor
Wills Eye
Other
Eligibility
40 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 22, 2026, 1:34 AM EDT
Recruiting Phase 2 Interventional

Treatment of Neonatal Encephalopathy With Oral Sildenafil Suspension to Repair Brain Injury Secondary to Birth Asphyxia

NCT06098833
View directory record Official record
Conditions
Neonatal Encephalopathy
Interventions
Sildenafil, Ora-Blend
Drug
Lead sponsor
Pia Wintermark
Other
Eligibility
0 Minutes to 48 Hours
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 22, 2026, 1:34 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Neuroprotection in Acute Ischemic Stroke

NCT03320018
View directory record Official record
Conditions
Stroke, Ischemic
Interventions
Hydrogen, Minocycline, Placebo Hydrogen, Placebo Minocycline
Drug · Other
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Sep 22, 2026, 1:34 AM EDT
Terminated Not applicable Interventional Results available

Feasibility Study of the Treatment of Acute Ischemic Stroke Using the NOVIS Transcarotid Neuroprotection System

NCT04881162
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
NOVIS Transcarotid Neuroprotection System (NPS)
Device
Lead sponsor
Silk Road Medical
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Sep 22, 2026, 1:34 AM EDT
Terminated Not applicable Interventional

Enhancing Facial Nerve Function With Omega-3 After Resection of Vestibular Schwannoma

NCT05116878
View directory record Official record
Conditions
Vestibular Schwannoma
Interventions
Omega-3, Placebo
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Sep 22, 2026, 1:34 AM EDT
Terminated Phase 2 Interventional Results available

NICardipine Neuroprotection in AortiC Surgery (NICNACS)

NCT00508118
View directory record Official record
Conditions
Aortic Aneurysm, Thoracic
Interventions
Nicardipine, 0.9% saline
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 31, 2014 · Synced Sep 22, 2026, 1:34 AM EDT
Completed Phase 2 Interventional Results available

Neuroprotection With Riluzole Patients With Early Multiple Sclerosis

NCT00501943
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Avonex (Interferon beta 1a), Riluzole, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Sep 22, 2026, 1:34 AM EDT
Completed Phase 1 Interventional

A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease

NCT05804383
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
BMS-984923, Placebo
Drug
Lead sponsor
Allyx Therapeutics
Industry
Eligibility
50 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
New Haven, Connecticut • West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 22, 2026, 1:34 AM EDT
Completed Phase 2 Interventional Results available

Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors

NCT03194906
View directory record Official record
Conditions
Glioma of Brain, Craniopharyngioma, Ependymoma, Germ Cell Tumor
Interventions
Memantine, Placebo, Cognitive Assessment
Drug · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
6 Years to 21 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 22, 2026, 1:34 AM EDT